» Articles » PMID: 23356739

Differential Effects of Garcinol and Curcumin on Histone and P53 Modifications in Tumour Cells

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2013 Jan 30
PMID 23356739
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Post-translational modifications (PTMs) of histones and other proteins are perturbed in tumours. For example, reduced levels of acetylated H4K16 and trimethylated H4K20 are associated with high tumour grade and poor survival in breast cancer. Drug-like molecules that can reprogram selected histone PTMs in tumour cells are therefore of interest as potential cancer chemopreventive agents. In this study we assessed the effects of the phytocompounds garcinol and curcumin on histone and p53 modification in cancer cells, focussing on the breast tumour cell line MCF7.

Methods: Cell viability/proliferation assays, cell cycle analysis by flow cytometry, immunodetection of specific histone and p53 acetylation marks, western blotting, siRNA and RT-qPCR.

Results: Although treatment with curcumin, garcinol or the garcinol derivative LTK-14 hampered MCF7 cell proliferation, differential effects of these compounds on histone modifications were observed. Garcinol treatment resulted in a strong reduction in H3K18 acetylation, which is required for S phase progression. Similar effects of garcinol on H3K18 acetylation were observed in the osteosarcoma cells lines U2OS and SaOS2. In contrast, global levels of acetylated H4K16 and trimethylated H4K20 in MCF7 cells were elevated after garcinol treatment. This was accompanied by upregulation of DNA damage signalling markers such as γH2A.X, H3K56Ac, p53 and TIP60. In contrast, exposure of MCF7 cells to curcumin resulted in increased global levels of acetylated H3K18 and H4K16, and was less effective in inducing DNA damage markers. In addition to its effects on histone modifications, garcinol was found to block CBP/p300-mediated acetylation of the C-terminal activation domain of p53, but resulted in enhanced acetylation of p53K120, and accumulation of p53 in the cytoplasmic compartment. Finally, we show that the elevation of H4K20Me3 levels by garcinol correlated with increased expression of SUV420H2, and was prevented by siRNA targeting of SUV420H2.

Conclusion: In summary, although garcinol and curcumin can both inhibit histone acetyltransferase activities, our results show that these compounds have differential effects on cancer cells in culture. Garcinol treatment alters expression of chromatin modifying enzymes in MCF7 cells, resulting in reprogramming of key histone and p53 PTMs and growth arrest, underscoring its potential as a cancer chemopreventive agent.

Citing Articles

Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.

Alalhareth I, Alyami S, Alshareef A, Ajeibi A, Al Munjem M, Elfifi A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006021 PMC: 11858621. DOI: 10.3390/ph18020207.


Repurposing Plant-Based Histone Acetyltransferase Inhibitors: A Review of Novel Therapeutic Strategies Against Drug-Resistant Fungal Biofilms.

Saravanan T, Raorane C, Ravichandran V, Rajasekharan S Curr Microbiol. 2024; 82(1):1.

PMID: 39532708 DOI: 10.1007/s00284-024-03971-8.


Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways.

Situmorang P, Ilyas S, Nugraha S, Syahputra R, Nik Abd Rahman N Front Pharmacol. 2024; 15:1387866.

PMID: 39104398 PMC: 11298448. DOI: 10.3389/fphar.2024.1387866.


Targeting SMAD-Dependent Signaling: Considerations in Epithelial and Mesenchymal Solid Tumors.

Runa F, Ortiz-Soto G, de Barros N, Kelber J Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543112 PMC: 10975212. DOI: 10.3390/ph17030326.


Histone Modification of Colorectal Cancer by Natural Products.

Geng Z, Chen M, Yu Q, Guo S, Chen T, Liu D Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631010 PMC: 10458348. DOI: 10.3390/ph16081095.


References
1.
Tjeertes J, Miller K, Jackson S . Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J. 2009; 28(13):1878-89. PMC: 2684025. DOI: 10.1038/emboj.2009.119. View

2.
Fraga M, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G . Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 37(4):391-400. DOI: 10.1038/ng1531. View

3.
Jin Q, Yu L, Wang L, Zhang Z, Kasper L, Lee J . Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 2010; 30(2):249-62. PMC: 3025463. DOI: 10.1038/emboj.2010.318. View

4.
Smith E, Cayrou C, Huang R, Lane W, Cote J, Lucchesi J . A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol. 2005; 25(21):9175-88. PMC: 1265810. DOI: 10.1128/MCB.25.21.9175-9188.2005. View

5.
Ferrari R, Pellegrini M, Horwitz G, Xie W, Berk A, Kurdistani S . Epigenetic reprogramming by adenovirus e1a. Science. 2008; 321(5892):1086-8. PMC: 2693122. DOI: 10.1126/science.1155546. View